About Nightstar Therapeutics (NASDAQ:NITE)
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-26.3
Forward P/E Ratio-19.63
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
Where is Nightstar Therapeutics' stock going? Where will Nightstar Therapeutics' stock price be in 2018?
5 brokers have issued 12-month price objectives for Nightstar Therapeutics' shares. Their forecasts range from $25.00 to $40.00. On average, they expect Nightstar Therapeutics' share price to reach $30.20 in the next year. View Analyst Ratings for Nightstar Therapeutics.
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include Inflarx (IFRX), Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), Rhythm Pharmaceuticals (RYTM), Karyopharm Therapeutics (KPTI), Urogen Pharma (URGN), Kura Oncology (KURA), Reata Pharmaceuticals (RETA), Sorrento Therapeutics (SRNE), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), CymaBay Therapeutics (CBAY), NuCana (NCNA), Aclaris Therapeutics (ACRS), Dicerna Pharmaceuticals (DRNA), Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX) and Insys Therapeutics (INSY).
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
When does Nightstar Therapeutics' lock-up period expire?
Nightstar Therapeutics' lock-up period expires on Tuesday, March 27th. Nightstar Therapeutics had issued 5,360,000 shares in its IPO on September 28th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Who owns Nightstar Therapeutics stock?
Who sold Nightstar Therapeutics stock? Who is selling Nightstar Therapeutics stock?
Who bought Nightstar Therapeutics stock? Who is buying Nightstar Therapeutics stock?
How do I buy Nightstar Therapeutics stock?
Shares of Nightstar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nightstar Therapeutics' stock price today?
One share of Nightstar Therapeutics stock can currently be purchased for approximately $13.15.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $369.52 million. Nightstar Therapeutics employs 23 workers across the globe.
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 215 Euston Road, LONDON, MA NW1 2BE, United Kingdom. The company can be reached via phone at +44-20-76112077 or via email at invest[email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NITE)MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Nightstar Therapeutics (NASDAQ:NITE)
No earnings announcements for this company have been tracked by MarketBeat.com
Nightstar Therapeutics (NASDAQ:NITE) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.67 EPS
Next Year EPS Consensus Estimate: $-1.55 EPS
Dividend History for Nightstar Therapeutics (NASDAQ:NITE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Nightstar Therapeutics (NASDAQ NITE)
No insider trades for this company have been tracked by MarketBeat.com
Nightstar Therapeutics (NASDAQ NITE) News Headlines
Nightstar Therapeutics (NASDAQ:NITE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Nightstar Therapeutics (NASDAQ:NITE) Income Statement, Balance Sheet and Cash Flow Statement
Nightstar Therapeutics (NASDAQ NITE) Stock Chart for Thursday, February, 22, 2018